Skip to content

Depression: all studies

Page 637 of 1,034: studies 6,361 to 6,370 of 10,336, newest first. Back to the depression overview

Research

Ketamine-enhanced prolonged exposure therapy in veterans with PTSD: A randomized controlled trial protocol.

Contemporary Clinical Trials August 1, 2024 Paulo R Shiroma, Paul Thuras, Melissa A Polusny et al. 7 citations

The 2023 VA/DoD Clinical Practice Guideline for the Management of PTSD recommends individual, manualized trauma-focused such as Prolonged Exposure (PE) over pharmacologic interventions for the primary treatment of PTSD. Unfortunately, clinical trials of trauma-based therapies in the military and veteran population showed that 30% to 50% of patients did not demonstrate clinically meaningful...

DOI: 10.1016/j.cct.2024.107569 (opens in new tab) Full text (opens in new tab) Prolonged exposure PTSD-Treatment Veterans-mental-health Ketamine-therapy +2

Psychedelic-assisted psychotherapy: where is the psychotherapy research?

Psychopharmacology August 1, 2024 Jacob S. Aday, David Horton, Gisele Fernandes-Osterhold et al. 39 citations

Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of PAP emphasize the importance of psychotherapeutic support before, during, and after ingestion of a psychedelic to maximize safety and clinical benefit. Despite this ubiquitous assumption, there has been...

Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT).

European Journal of Pharmaceutical Sciences August 1, 2024 Christopher G Witowski, Mika R Hess, Nate T Jones et al. 7 citations

There is considerable evidence from the literature that psychedelics, such as N,N-dimethyltryptamine (DMT), are safe and effective treatments for depression. However, clinical administration to induce psychedelic effects and expensive psychotherapy-assisted treatments likely limit accessibility to the average patient. There is emerging evidence that DMT promotes positive behavioral changes in...

Development and Effectiveness of Mindfulness-based Well-being Program for Teachers

The Korea Association of Yeolin Education July 31, 2024

In this study, a mindfulness-based intervention program for teachers and empirically validated the effects on teachers’ stress and subjective well-being was developed. More specifically, based on the latest neuroscience and positive psychology research on mindfulness, we developed a mindfulness-based well-being program for teachers that incorporated mindfulness meditation and positive...

MDMA Therapy for PTSD: Inching Closer to—or Farther From—Approval?

The Senior Care Pharmacist July 31, 2024 Leigh Davitian 1 citation

In recent years, scientists have initiated a renaissance in psychedelic research following decades of prohibition. Compounds such as ketamine, LSD, and psilocybin 'once primarily associated with recreational use' are now being investigated for their therapeutic potential, with promising results. An estimated 40-60% of people with post-traumatic stress disorder (PTSD) do not respond to selective...

From chaos to kaleidoscope: Exploring factors in psychedelic self-treatment for mental health conditions.

Journal of Psychopharmacology July 29, 2024 Claire Walker, Timothy Piatkowski, Jason Ferris et al. 4 citations

INTRODUCTION: This study explores how individuals self-treat psychiatric conditions with psychedelics outside medical guidance bridging the gap in understanding unregulated therapeutic use. AIMS: The primary objective was to extract specific factors underlying the effects of psychedelics, exploring their relationship with the need for medication, particularly for mental health conditions like...

DOI: 10.1177/02698811241265762 (opens in new tab) Full text (opens in new tab) Mental-health Psychedelics Self-treatment Depression-anxiety +1

mTORC1 activation in presumed classical monocytes: observed correlation with human size variation and neuropsychiatric disease.

Aging July 26, 2024 Karl Berner, Naci Oz, Alaattin Kaya et al. 1 citation

Gain of function disturbances in nutrient sensing are likely the largest component in human age-related disease. Mammalian target of rapamycin complex 1 (mTORC1) activity affects health span and longevity. The drugs ketamine and rapamycin are effective against chronic pain and depression, and both affect mTORC1 activity. Our objective was to measure phosphorylated p70S6K, a marker for mTORC1...

The Relation Between the CBT and Characters in the Dream Content of the Depressed People

International Journal For Multidisciplinary Research July 25, 2024 Dr Nandigam Jagan Mohan Laxmi -

Abstract: The study on “The Relation between the CBT and Characters in the Dream Content of the Depressed People” investigates the influence of Cognitive Behaviour Therapy (CBT) on the characters present in the dream content of individuals diagnosed with depression, examining variations across gender and educational levels. Employing a mixed-methods approach, this research integrates both...

Assessing the Impact of the Mindfulness-Based Body Scan Technique on Sleep Quality in Multiple Sclerosis Using Objective and Subjective Assessment Tools: Single-Case Study.

JMIR Formative Research July 25, 2024 Ioannis Iliakis, Maria Anagnostouli, George P Chrousos 1 citation

Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system, often leading to poor sleep quality and diminished quality of life (QoL) for affected patients. Sleep disturbances in MS do not always correlate linearly with other symptoms such as anxiety, depression, fatigue, or pain. Various approaches, including stress reduction techniques such as...

Exploring Legal Frameworks for the Clinical Use of Psychedelic Substances in Mental Health Treatment

July 25, 2024 Anggraeni Endah Kusumaningrum, Ardianto Sucinta

In recent years, interest in the use of psychedelic substances in the treatment of mental disorders has increased significantly. Recent research shows the potential of psychedelic substances such as psilocybin, LSD, and MDMA to treat disorders such as major depression, post-traumatic stress disorder (PTSD), and substance addiction. However, the clinical use of psychedelic substances remains...

DOI: 10.56444/ulrev.v8i2.5241 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Psilocybin treatment Psychedelic medicine Innovative therapy +17